|
rs10865710
|
|
Obesity
|
|
0.010 |
GeneticVariation
|
BEFREE |
The PPARγ rs10865710 C allele carriers were found to be less likely to suffer from VPA-induced obesity compared with GG genotype carriers (OR, 0.04; 95%CI, 0.01-0.12; P < 0.001).
|
29984389 |
2018 |
|
rs10865710
|
|
Coronary Artery Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
CAD susceptibility was higher in those with homozygous mutant of rs10865710, rs1805192 and rs4646903 than those with wild-type homozygotes, OR (95%CI) were 1.47 (1.15-1.92), 1.69 (1.27-2.09) and 1.72 (1.35-2.32), respectively.
|
28415751 |
2017 |
|
rs10865710
|
|
Asthma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Significant associations were found between rs10766197 of CYP2R1, rs7041 and rs4588 of CG, rs4646536 of CYP27B1, rs2228570, rs7975232, and rs1544410 of VDR, as well as rs1805192 and rs10865710 of PPAR and susceptibility to and prognosis of childhood bronchial asthma, providing novel targets for treating the disorder.
|
28590769 |
2017 |
|
rs10865710
|
|
Cardiovascular Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found a significant association between genotypes of variants in rs10865710 and rs1805192 with increased CVD risk and a potential gene-gene interaction between rs1805192 and smoking.
|
26475999 |
2016 |
|
rs10865710
|
|
Septicemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The rs10865710 polymorphism in the PPARγ gene might be used to assess the risk of sepsis and multiple organ dysfunction syndrome (MODS) in trauma patients.
|
27023591 |
2016 |
|
rs10865710
|
|
Sepsis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The rs10865710 polymorphism in the PPARγ gene might be used to assess the risk of sepsis and multiple organ dysfunction syndrome (MODS) in trauma patients.
|
27023591 |
2016 |
|
rs10865710
|
|
Systemic Scleroderma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the discovery cohort, a single PPARG intronic SNP (rs10865710) was associated with SSc (p=0.010; odds ratio=1.52 per C allele, 95% confidence interval 1.10-2.08).
|
25986483 |
2015 |
|
rs10865710
|
|
Associated Pulmonary Arterial Hypertension
|
|
0.010 |
GeneticVariation
|
BEFREE |
The rs10865710 C allele was also associated with pulmonary arterial hypertension in the French SSc cohort (p=0.002; odds ratio=2.33 per C allele, 95% confidence interval 1.34-4.03).
|
25986483 |
2015 |
|
rs10865710
|
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
We genotyped three potentially functional single nucleotide polymorphisms (SNPs) using Taqman - rs3734254 of the gene PPARD and rs10865710 and rs1801282 of the gene PPARG - and investigated their associations with lung and UADT cancer survival using Cox regression.
|
25043640 |
2014 |
|
rs10865710
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We genotyped three potentially functional single nucleotide polymorphisms (SNPs) using Taqman - rs3734254 of the gene PPARD and rs10865710 and rs1801282 of the gene PPARG - and investigated their associations with lung and UADT cancer survival using Cox regression.
|
25043640 |
2014 |
|
rs10865710
|
|
Non-alcoholic Fatty Liver Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
The G allele frequency of rs10865710 in NAFLD group (41.1%) was significantly higher than that (34.8%) in controls (p = 0.03).
|
22820754 |
2012 |
|
rs10865710
|
|
Chronic Kidney Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
Subsequent multivariable logistic regression analysis with adjustment for covariates as well as a stepwise forward selection procedure revealed that the T --> C (Val591Ala) polymorphism of APOB (rs679899), the -681C --> G polymorphism of PPARG (rs10865710), the T --> C (Cys1367Arg) polymorphism of WRN (rs1346044), the -850C --> T polymorphism of TNF (rs1799724), the -219G --> T polymorphism of APOE (rs405509), the C --> T polymorphism of PTGS1 (rs883484) and the 41A --> G (Glu14Gly) polymorphism of ACAT2 (rs9658625) were significantly (P<0.05) associated with the prevalence of CKD.
|
19282863 |
2009 |
|
rs1151996
|
|
Polycystic Ovary Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
The following variant alleles were significantly associated with decreased PCOS risk: <i>ESR1</i> rs9340799 (<i>P</i> = 0.000), <i>PPARG</i> rs709154 (<i>P</i> = 0.013), and rs1151996 (<i>P</i> = 0.013), <i>HMGA2</i> rs2272046 (<i>P</i> = 0.000), <i>MTHFR</i> rs1801133 (<i>P</i> = 0.000).
|
30214429 |
2018 |
|
rs1151999
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
The PPAR-γ TCCA haplotype derived from SNPs in introns 4 (rs4135263), 5 (rs1151999), and 6 (rs709149 and rs709154) showed a strong protective effect against AD in APOE ε4 allele noncarriers (p=0.001, permutation p=0.006, Bonferroni corrected p=0.021), with a frequency of 39% in cases and 50% in controls.
|
19660836 |
2011 |
|
rs11715073
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.010 |
GeneticVariation
|
BEFREE |
Three-site haplotype analysis in the PPARG locus using the 2 marginally associated SNPs (P/rs11715073 and P/rs3892175) in combination with Pro12 Ala (P/rs1801282) revealed a strong association of 1 "risk" (CGC) (P = .003, permutation P = .015) and 1 "protective" (CAC) (P = .001, permutation P = .005) haplotype associated with T2D.
|
19846176 |
2010 |
|
rs1175543
|
|
Hypertensive disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Moreover, among the eight SNPs not individually associated with hypertension (rs12631819, rs2920502, rs1175543, and rs2972164 in the PPARG gene, and rs2638360, rs1492100, rs5182, and rs275646 in the AGTR1 gene), the two-locus model involving rs12631819 and rs5182 demonstrated increased susceptibility to hypertension, and the five-locus model involving rs12631819, rs2920502, rs2972164, rs5182, and rs2638360 demonstrated a significantly decreased risk of hypertension.
|
29266977 |
2018 |
|
rs1175543
|
|
Metabolic Syndrome X
|
|
0.010 |
GeneticVariation
|
BEFREE |
The PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 were associated with MS in Kazakh subjects.
|
25366759 |
2014 |
|
rs1175543
|
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that decreased lung cancer risk was statistically significantly associated with seven SNPs (P = 0.0004 for rs13073869 and 0.0130 for rs1899951 in a dominant model; P = 0.0310 for rs4135247 in a log-additive model; and P = 0.0468 for rs2972162, 0.0175 for rs709151, 0.0172 for rs11715541 and 0.0386 for rs1175543 in an overdominant model).
|
18187557 |
2008 |
|
rs1175543
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that decreased lung cancer risk was statistically significantly associated with seven SNPs (P = 0.0004 for rs13073869 and 0.0130 for rs1899951 in a dominant model; P = 0.0310 for rs4135247 in a log-additive model; and P = 0.0468 for rs2972162, 0.0175 for rs709151, 0.0172 for rs11715541 and 0.0386 for rs1175543 in an overdominant model).
|
18187557 |
2008 |
|
rs1175543
|
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that decreased lung cancer risk was statistically significantly associated with seven SNPs (P = 0.0004 for rs13073869 and 0.0130 for rs1899951 in a dominant model; P = 0.0310 for rs4135247 in a log-additive model; and P = 0.0468 for rs2972162, 0.0175 for rs709151, 0.0172 for rs11715541 and 0.0386 for rs1175543 in an overdominant model).
|
18187557 |
2008 |
|
rs121909244
|
|
Impaired glucose tolerance
|
|
0.010 |
GeneticVariation
|
BEFREE |
Nes<sup>Cre</sup>/PPARγ-P467L mice fed either control diet or high-fat diet displayed impaired glucose tolerance yet exhibited increased sensitivity to exogenous insulin and increased insulin receptor signaling in white adipose tissue, liver, and skeletal muscle.
|
27575030 |
2016 |
|
rs121909244
|
|
Hyperglycemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
The dominant-negative P467L mutation in peroxisome proliferator activated receptor-γ (PPARγ) was identified in insulin-resistant patients with hyperglycemia and lipodystrophy.
|
20724579 |
2010 |
|
rs121909244
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a randomized, placebo-controlled, double-blind, crossover study, 24 subjects with type 2 diabetes and one subject with partial lipodystrophy and diabetes due to dominant-negative mutation in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene (P467L) received placebo and rosiglitazone for 3 months.
|
15855323 |
2005 |
|
rs121909244
|
|
Diabetes Mellitus
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a randomized, placebo-controlled, double-blind, crossover study, 24 subjects with type 2 diabetes and one subject with partial lipodystrophy and diabetes due to dominant-negative mutation in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene (P467L) received placebo and rosiglitazone for 3 months.
|
15855323 |
2005 |
|
rs121909244
|
|
Diabetes
|
|
0.010 |
GeneticVariation
|
BEFREE |
In a randomized, placebo-controlled, double-blind, crossover study, 24 subjects with type 2 diabetes and one subject with partial lipodystrophy and diabetes due to dominant-negative mutation in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene (P467L) received placebo and rosiglitazone for 3 months.
|
15855323 |
2005 |